BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of The American Academy of Dermatology Année : 2020

BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors

, (1) , , , , , (2, 3) , (4) , , (5, 6) , , , (7) , , (4) , , (8)
1
2
3
4
5
6
7
8

Résumé

Background: Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1(PD-L1) therapy frequently entails immune-related adverse events (irAEs), and biomarkers to predict irAEs are lacking. Although checkpoint inhibitors have been found to reinvigorate T cells, the relevance of autoantibodies remains elusive. Objective: Our aim was to explore whether IgG autoantibodies directed against coexpressed antigens by tumor tissue and healthy skin correlate with skin irAEs and therapy outcome. Methods: We measured skin-specific IgG via enzyme-linked immunosorbent assay in patients with non-small cell lung cancer (NSCLC) who received anti-PD1/PD-L1 treatment between July 2015 and September 2017 at the Kantonsspital St. Gallen. Sera were sampled at baseline and during therapy after 8 weeks. Results: Analysis of publicly available tumor expression data revealed that NSCLC and skin coexpress BP180, BP230, and type VII collagen. A skin irAE developed in 16 of 40 recruited patients (40%). Only elevated anti-BP180 IgG at baseline significantly correlated with the development of skin irAEs (P = .04), therapy response (P = .01), and overall survival (P = .04). Limitations: The patients were recruited in a single tertiary care center. Conclusions: Our data suggest that the level of anti-BP180 IgG of NSCLC patients at baseline is associated with better therapy response and overall survival and with a higher probability to develop skin irAEs during anti-PD1/PD-L1 treatment.

Dates et versions

hal-03548805 , version 1 (31-01-2022)

Identifiants

Citer

Omar Hasan Ali, David Bomze, Sandra S. Ring, Fiamma Berner, Mirjam Fassler, et al.. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. Journal of The American Academy of Dermatology, 2020, 82 (4), pp.854-861. ⟨10.1016/j.jaad.2019.08.045⟩. ⟨hal-03548805⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More